INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Option exerciseVerified data

Berman David M reported IMCR

HEAD OF R&D · Immunocore Holdings plc · Ordinary Shares

Side
M
Value
—
Shares
11.8K
Price
—
Executed
Feb 17, 2026
Disclosed
Feb 19, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 17 executedFeb 19, 2026 disclosed

IMCR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
2/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+1 / 15

    Routine: 6 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IMCR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    BI
    Bell John IrvingDirector
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    27.5K sh
    		May 27, 2026May 28, 2026
    traded May 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KS
    Kaul SiddharthDirector
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    27.5K sh
    		May 27, 2026May 28, 2026
    traded May 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    HS
    Herbst Roy StevenDirector
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    27.5K sh
    		May 27, 2026May 28, 2026
    traded May 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RJ
    Ratcliffe Peter JohnDirector
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    27.5K sh
    		May 27, 2026May 28, 2026
    traded May 27, 2026
    		+1dSEC FORM 4

    Evidence

    9
    PW
    Pao WilliamDirector
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    27.5K sh
    		May 27, 2026May 28, 2026
    traded May 27, 2026
    		+1dSEC FORM 4

    Evidence

    21
    SA
    St Leger Tina AmberCHIEF HR OFFICER
    IMCRImmunocore Holdings plc
    Option exercise
    		M—
    2,119 sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    34
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Open-market sale
    		SELL$193K
    5,965 sh
    		Feb 18, 2026Feb 19, 2026
    traded Feb 18, 2026
    		+1dSEC FORM 4

    Evidence

    34
    SA
    St Leger Tina AmberCHIEF HR OFFICER
    IMCRImmunocore Holdings plc
    Open-market sale
    		SELL$32K
    1,000 sh
    		Feb 18, 2026Feb 19, 2026
    traded Feb 18, 2026
    		+1dSEC FORM 4

    Evidence

    10
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise
    		M—
    11.8K sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CA
    Coy Travis AlanChief Financial Officer
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    95.6K sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CA
    Coy Travis AlanChief Financial Officer
    IMCRImmunocore Holdings plc
    Grant or award
    		A—
    33.4K sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SA
    St Leger Tina AmberCHIEF HR OFFICER
    IMCRImmunocore Holdings plc
    Option exercise
    		M—
    2,119 sh
    		Feb 17, 2026Feb 19, 2026
    traded Feb 17, 2026
    		+2dSEC FORM 4

    Evidence

    0
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M—
    31.3K sh
    		Dec 4, 2025Dec 8, 2025
    traded Dec 4, 2025
    		+4dSEC FORM 4

    Evidence

    1
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M$547K
    31.3K sh
    		Dec 4, 2025Dec 8, 2025
    traded Dec 4, 2025
    		+4dSEC FORM 4

    Evidence

    22
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Open-market sale · 10b5-1 plan
    		SELL$1.26M
    31.3K sh
    		Dec 4, 2025Dec 8, 2025
    traded Dec 4, 2025
    		+4dSEC FORM 4

    Evidence

    0
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M$9,987
    572 sh
    		Dec 5, 2025Dec 8, 2025
    traded Dec 5, 2025
    		+3dSEC FORM 4

    Evidence

    13
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Open-market sale · 10b5-1 plan
    		SELL$23K
    572 sh
    		Dec 5, 2025Dec 8, 2025
    traded Dec 5, 2025
    		+3dSEC FORM 4

    Evidence

    0
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M—
    572 sh
    		Dec 5, 2025Dec 8, 2025
    traded Dec 5, 2025
    		+3dSEC FORM 4

    Evidence

    0
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M—
    5,521 sh
    		Nov 28, 2025Dec 1, 2025
    traded Nov 28, 2025
    		+3dSEC FORM 4

    Evidence

    1
    BM
    Berman David MHEAD OF R&D
    IMCRImmunocore Holdings plc
    Option exercise · 10b5-1 plan
    		M—
    69.4K sh
    		Nov 26, 2025Dec 1, 2025
    traded Nov 26, 2025
    		+5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001955244-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 17, 2026
    Published
    Feb 19, 2026
    Ingested by INSIDER
    Nov 5, 04:16 UTC
    Last re-read
    Nov 5, 04:16 UTC

    Extracted facts

    Filer
    Berman David M
    Role
    HEAD OF R&D
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Immunocore Holdings plc
    Ticker
    IMCR
    Shares
    11.8K
    Price per share
    $0
    Execution date (reported)
    Feb 17, 2026
    Owned after transaction
    11.8K shares
    Days from execution to publication
    2

    What this establishes

    Berman David M filed this Form 4 reporting a option exercise of IMCR on Feb 17, 2026. It became public on Feb 19, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    HEAD OF R&D
    Berman David Mcik:0001955244
    Issuer
    Immunocore Holdings plccik:0001671927

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.